InnoSIGN

InnoSIGN is a private, pre-revenue diagnostics platform company developing a proprietary bioinformatics solution for disease interpretation. Its Comprehensive Pathway Analysis (CPA) platform uses a proprietary algorithm to analyze RNA-sequencing data, inferring the activity of key cell signaling pathways to provide deeper, actionable insights beyond single mutations. The platform is positioned to support the full drug development continuum, from preclinical research to companion diagnostics, primarily in oncology but also in autoimmune and metabolic diseases. The company seeks to address the industry's reliance on single biomarkers by offering a systems-level view of disease mechanisms.

Comprehensive Pathway Analysis (CPA) platform: A proprietary bioinformatics platform that analyzes RNA-sequencing data to infer the functional activity of 12 key cell signaling pathways (e.g., PI3K, MAPK, TGFβ, Wnt). It uses a proprietary algorithm to translate complex omics data into actionable insights on disease drivers, moving beyond single-mutation analysis.

InnoSIGN competes in the computational diagnostics and biomarker discovery space. Direct and indirect competitors include large genomic profiling companies (e.g., Foundation Medicine, Guardant Health), other multi-omics and pathway analysis startups, and the internal bioinformatics capabilities of large pharmaceutical companies. Differentiation relies on the proprietary algorithm and focus on functional pathway activity.